Form 4: Apogee Therapeutics CFO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock on March 2, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported the sale of 2,000 shares of common stock.
• The transactions occurred on March 2, 2026, across four separate sales.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
• The shares were sold at weighted average prices ranging from $68.27 to $71.66 per share.
• Following these transactions, Ms. Henderson beneficially owns 181,371 shares of Apogee Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider sales under a Rule 10b5-1 plan are routine and generally do not indicate a shift in company fundamentals or management's outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a pre-arranged Rule 10b5-1 plan are common and typically do not signal a change in management's confidence in the company's prospects, as they are scheduled in advance to avoid accusations of trading on material non-public information. Such sales are often for personal financial planning, diversification, or liquidity purposes.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by a CFO under a pre-arranged plan is unlikely to have a significant impact on shareholder sentiment or the company's valuation.

Key Dates

Recommendation

The reported insider sale is a routine transaction executed under a pre-arranged 10b5-1 trading plan. Such sales are typically for personal financial management and do not reflect a change in the company's fundamental outlook or the insider's confidence. Therefore, this filing alone does not warrant a change in investment recommendation, and a 'hold' stance is appropriate, pending further fundamental analysis.

Keywords

Apogee Therapeutics, APGE, Insider Sale, Form 4, Jane Henderson, CFO, 10b5-1 Plan, Common Stock